Close

TCR-Like Antibody Products

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Cancer immunotherapy is regarded as the most important scientific breakthrough in the field of tumor treatment, and antibody therapy is the core of this breakthrough. Despite the great success in recent years, it is still difficult to target intracellular antigens of tumor cells with traditional antibodies, and novel therapeutic strategies are needed. T cell receptor (TCR)-like antibodies include novel antibodies that can recognize peptide/MHC complexes on the surface of tumor cells. TCR-like antibodies can perform specific and important anti-tumor immunity through several different molecular mechanisms. At present, TCR-like antibody therapy has been successful in melanoma, leukemia, breast, colon, and prostate cancer models, prompting researchers to seek further breakthroughs in this field.

Equipped with high-end technology and doctorate-level scientists, Creative Biolabs has long been a well-known service provider in the field of antibody development and cell therapy. After years of exploration, we have developed a comprehensive list of TCR antibody products targeting the peptide / MHC complex which would be promising targets for the engineered TCR-T cell therapy.

In addition to TCR-Like Antibody products, Creative Biolabs also provides innovative TCR-Like Antibody services from immunogen production to antibody characterization. You can explore more details at TCR-Like Antibody Services to accelerate the development of your therapeutic antibody drugs. Please feel free to contact us to find the custom solution that suits your specific needs.

Advantages of TCR-like Antibodies Over Other Immunotherapies

The biggest advantage of TCR-like antibodies is their ability to target intracellular tumor antigens with minimal in vitro manipulation. TCR-T adoptive cell therapy can also target intracellular antigens, but requires a more complicated preparation process. In addition, the transduced antigen-specific TCR may not match the endogenous wild-type TCR because both TCRs are present in the same T cell. However, TCR-like antibodies are relatively easy to prepare and store, and can be used directly. Through the binding of the Fab region to the peptide/MHC complex, the Fc region of the TCR-like antibody can bind to the Fcγ receptor (FcγR) expressed by the patient's NK cells, monocytes or macrophages, and activate these cells to kill tumors.

Schematics of T cell receptor (TCR) and TCR-like receptor.

Fig.1 Schematics of T cell receptor (TCR) and TCR-like receptor.

Please browse the target below to find the right product for you.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.